Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II
- 14 June 2007
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (14), 3267-3273
- https://doi.org/10.1021/jm070133w
Abstract
Inhibition of glutamate carboxypeptidase II (GCPII) has been shown to be neuroprotective in multiple preclinical models in which dysregulated glutamatergic transmission is implicated. Herein, we report crystal structures of the human GCPII complexed with three glutamate mimetics/derivatives, 2-(phosphonomethyl)pentanedioic acid (2-PMPA), quisqualic acid (QA), and L-serine O-sulfate (L-SOS), at 1.72, 1.62, and 2.10 A resolution, respectively. Despite the structural differences between the distal parts of the inhibitors, all three compounds share similar binding modes in the pharmacophore (i.e., S1') pocket of GCPII, where they are stabilized by a combination of polar and van der Waals interactions. The structural diversity of the distal parts of the inhibitors leads to rearrangements of the S1' site that are necessary for efficient interactions between the enzyme and an inhibitor. The set of structures presented here, in conjunction with the available biochemical data, illustrates a flexibility of the GCPII pharmacophore pocket and highlights the structural features required for potent GCPII inhibition. These findings could facilitate the rational structure-based drug design of new GCPII inhibitors in the future.Keywords
This publication has 33 references indexed in Scilit:
- Expression of glutamate carboxypeptidase II in human brainNeuroscience, 2007
- NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluRJournal of Neurochemistry, 2004
- Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the ratNeuropeptides, 2003
- Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis modelsProceedings of the National Academy of Sciences, 2003
- Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase IIJournal of Neurochemistry, 2002
- Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-βEuropean Journal of Pharmacology, 2001
- Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injuryNature Medicine, 1999
- The Role of Excitotoxicity in Neurodegenerative DiseasePharmacology & Therapeutics, 1999
- Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cellsNeuroscience, 1998
- Synthesis of acyclic and dehydroaspartic acid analogs of Ac-Asp-Glu-OH and their inhibition of rat brain N-acetylated .alpha.-linked acidic dipeptidase (NAALA dipeptidase)Journal of Medicinal Chemistry, 1990